Resverlogix Corp 뉴스 - RVX | 주식 토론토 증권거래소

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF...

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Appointment of New Chief Scientific Officer

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation...

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company...

Resverlogix Announces One-Year Extension of Debenture

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global...

Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to...

Resverlogix Announces Corporate Update Webcast and Conference Call

CALGARY, Alberta, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment

CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”...

alvaroc2 8 년 전

TA breaking 2,50 try 3 $.

👍️0

alvaroc2 8 년 전

No analist cover at the moment, when news came.....

👍️0

alvaroc2 8 년 전

Good evening clase 2,41 near high 2,47,good news and many conferences in march and april.

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Resverlogix Corp (RVX)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

RVX 뉴스

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

Resverlogix Announces Corporate Update Webcast and Conference Call

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment

RVX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Resverlogix Corp (RVX) 뉴스

Resverlogix Corp (RVX)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

RVX 뉴스

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

Resverlogix Announces Corporate Update Webcast and Conference Call

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment

RVX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거